Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.77 |
| ▸ | FTO | Q9C0B1 | 4/20 | 0.77 |
| ▸ | COMT | P21964 | 4/20 | 0.77 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.77 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.77 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.77 |
| ▸ | EGFR | P00533 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14573318 | 1.00 | MEN1 (0.77) | MEN1KMT2AFTOCOMTABCC3 | |
| SCHEMBL1405287 | 1.00 | MEN1 (0.77) | MEN1KMT2AFTOCOMTABCC3 | |
| SCHEMBL4933461 | 0.91 | FTO (0.75) | MEN1KMT2AFTOCOMTABCC3 | |
| SCHEMBL4855685 | 0.91 | KMT2A (0.75) | MEN1KMT2AFTOCOMTABCC3 | |
| SCHEMBL4855680 | 0.91 | KMT2A (0.75) | MEN1KMT2AFTOCOMTABCC3 | |
| SCHEMBL4609378 | 0.90 | MEN1 (0.68) | MEN1KMT2AFTOCOMTABCC3 | |
| SCHEMBL4609366 | 0.90 | MEN1 (0.68) | MEN1KMT2AFTOCOMTABCC3 | |
| SCHEMBL5323630 | 0.90 | FTO (0.71) | MEN1KMT2AFTOCOMTABCC3 | |
| SCHEMBL5323628 | 0.90 | FTO (0.71) | MEN1KMT2AFTOCOMTABCC3 | |
| SCHEMBL4939474 | 0.90 | FTO (0.74) | MEN1KMT2AFTOCOMTABCC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006064296-A1 | PROCESS FOR THE PREPARATION OF (E)-N,N-DIETHYL-2-CYANO-3(3,4-DIHYDROXY-5-NITRO-PHENYL)-ACRYLAMIDE IN STABLE POLYMORPHIC FORM AND INTERMEDIATES OF THE PROCESS | ALKALOIDA KUTATO ES FEJLESZTÖ KFT (HU) | 2006-06-22 | — | — | WO | claimed |
| US-20150191430-A1 | CONJUGATES OF HUPERZINE AND ANALOGS THEREOF | BISCAYNE NEUROTHERAPEUTICS, INC. | 2015-07-09 | — | — | US | disclosed |
| EP-1699753-B1 | IMPROVED PROCESS FOR THE PREPARATION OF ENTACAPONE | SUVEN LIFE SCIENCES LTD (IN) | 2014-11-26 | — | — | EP | disclosed |
| WO-2014164667-A1 | DENGUE AND WEST NILE VIRUS PROTEASE INHIBITORS | GEORGETOWN UNIVERSITY (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2013149566-A1 | PROCESS FOR THE PREPARATION OF ENTACAPONE AND ITS INTERMEDIATE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013149566-A1 | PROCESS FOR THE PREPARATION OF ENTACAPONE AND ITS INTERMEDIATE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2013-10-10 | — | — | WO | disclosed |
| EP-1935873-B1 | A process for the preparation of entacapone | DIPHARMA FRANCIS SRL (IT) | 2011-03-09 | — | — | EP | disclosed |
| US-7750177-B2 | Process for the preparation of entacapone | DIPHARMA FRANCIS S.R.L. (IT) | 2010-07-06 | — | — | US | disclosed |
| WO-2008119793-A1 | PROCESS FOR THE PREPARATION OF ENTACAPONE AND INTERMEDIATES THEREOF | Esteve Química, S.A. (ES) | 2008-10-09 | — | — | WO | disclosed |
| EP-1978014-A1 | Process for the preparation of entacapone and intermediates thereof | ESTEVE QUIMICA, S.A. (ES) | 2008-10-08 | — | — | EP | disclosed |
| EP-1935873-A1 | A process for the preparation of entacapone | Dipharma Francis S.r.l. (IT) | 2008-06-25 | — | — | EP | disclosed |
| US-20080146829-A1 | PROCESS FOR THE PREPARATION OF ENTACAPONE | DIPHARMA FRANCIS S.R.L. (IT) | 2008-06-19 | — | — | US | disclosed |
| US-7385072-B2 | Methods for the preparation of Entacapone | SUVEN LIFE SCIENCES (IN) | 2008-06-10 | — | — | US | disclosed |
| US-7385072-B2 | Methods for the preparation of Entacapone | SUVEN LIFE SCIENCES (IN) | 2008-06-10 | — | — | US | disclosed |
| US-20080103191-A1 | ENTACAPONE-DERIVATIVES | SCHWARZ PHARMA AG (DE) | 2008-05-01 | — | — | US | disclosed |
| WO-2007144169-A2 | ENTACAPONE-DERIVATIVES | SCHWARZ PHARMA AG (DE) | 2007-12-21 | — | — | WO | disclosed |
| US-20070060767-A1 | Methods for the preparation of Entacapone | SUVEN LIFE SCIENCES (IN) | 2007-03-15 | — | — | US | disclosed |
| US-20070060767-A1 | Methods for the preparation of Entacapone | SUVEN LIFE SCIENCES (IN) | 2007-03-15 | — | — | US | disclosed |
| US-20070060767-A1 | Methods for the preparation of Entacapone | SUVEN LIFE SCIENCES (IN) | 2007-03-15 | — | — | US | disclosed |
| WO-2005063693-A1 | IMPROVED PROCESS FOR THE PREPARATION OF ENTACAPONE | SUVEN LIFE SCIENCES LTD (IN) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103191-A1 | ENTACAPONE-DERIVATIVES | ENTPD5, ENTPD3, ENTPD1 | MEN1 1023/4885KMT2A 4545/4885FTO 2243/4885 |
| US-20080146829-A1 | PROCESS FOR THE PREPARATION OF ENTACAPONE | ADCYAP1R1, AVPR2, AVPR1A | MEN1 1754/4885KMT2A 4521/4885FTO 1444/4885 |
| US-20150191430-A1 | CONJUGATES OF HUPERZINE AND ANALOGS THEREOF | HTT, HNMT, GAP43 | MEN1 2077/4885KMT2A 1096/4885FTO 3877/4885 |
| US-20070060767-A1 | Methods for the preparation of Entacapone | OTC, NAAA, GNE | MEN1 1942/4885KMT2A 676/4885FTO 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.